文献速递心脑血管急症重症综合管理与镇静镇痛

心脏骤停后神经元特异性烯醇化酶预后准确性的混杂因素:一项回顾性队列研究

Confounders for prognostic accuracy of neuron-specific enolase after cardiac arrest: A retrospective cohort study.
PubMed 文献 · Resuscitation · 2023-09-06
一句话结论心脏骤停后48-96小时NSE>100 µg/L高特异度预测不良神经预后,NSE<17 µg/L提示无严重缺氧缺血性脑病,需考虑溶血等混杂因素。

该回顾性队列研究基于心脏骤停登记资料,分析356例心脏骤停后3天存活者中,NSE血清浓度及溶血指数(h-index)在心脏骤停后48-96小时测定的情况,以出院时脑功能分类评分(CPC)评估神经预后。结果显示,NSE阈值60 µg/L预测不良神经预后(CPC 4-5)的特异度为92%(86-95%)、敏感度为73%(66-79%);非溶血样本特异度94%(89-97%)、敏感度70%(62-76%)。阈值100 µg/L时特异度98%(95-100%,全部样本)和99%(95-100%,非溶血样本),敏感度58%(51-65%)和55%(47-63%)。结论认为NSE>100 µg/L高特异度预测不良神经预后,NSE<17 µg/L提示无严重缺氧缺血性脑病,需考虑溶血和其他混杂因素。

要点

  • 在356例心脏骤停后3天存活者中,NSE阈值100 µg/L预测不良神经预后(CPC 4-5)的特异度在全部样本为98%(95-100%),非溶血样本为99%(95-100%)。
  • NSE阈值60 µg/L预测不良神经预后的特异度92%(86-95%)、敏感度73%(66-79%);非溶血样本特异度94%(89-97%)、敏感度70%(62-76%)。
  • 溶血样本28例(7.9%),溶血影响NSE预测准确性,分析时需排除h-index大于50的样本。
  • NSE低于17 µg/L的9例患者均为CPC 5,但均有缺氧缺血性脑病以外的合理死亡原因。
  • 良好神经预后患者中NSE升高的可能混杂因素包括ECMO、恶性肿瘤、输血和急性脑病。

适用人群与场景

  • 心脏骤停后3天存活者,来自心脏骤停登记资料。
  • 回顾性分析,纳入356例幸存者。

诊断标准与关键阈值

  • 神经预后评估采用出院时脑功能分类评分(CPC),分别以CPC 1-3和CPC 1-2作为良好神经预后标准。
  • NSE血清浓度和溶血指数(h-index)在心脏骤停后48-96小时测定。
  • 溶血样本定义为h-index大于50。

红旗征与不能漏的情况

  • NSE低于17 µg/L的9例患者均为CPC 5,但均有缺氧缺血性脑病以外的合理死亡原因,提示低NSE不能排除其他原因导致的死亡。

研究设计与关键结果

  • 研究类型:回顾性队列研究,样本量356例心脏骤停后3天存活者。
  • 溶血检出28例(7.9%)。
  • NSE阈值60 µg/L预测不良神经预后(CPC 4-5):全部样本特异度92%(86-95%)、敏感度73%(66-79%);非溶血样本特异度94%(89-97%)、敏感度70%(62-76%)。
  • NSE阈值100 µg/L预测不良神经预后:全部样本特异度98%(95-100%)、敏感度58%(51-65%);非溶血样本特异度99%(95-100%)、敏感度55%(47-63%)。
  • 良好神经预后患者中NSE升高的可能混杂因素包括ECMO、恶性肿瘤、输血和急性脑病。
  • NSE低于17 µg/L的9例患者CPC为5,均有缺氧缺血性脑病以外的合理死亡原因。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,NSE浓度高于100 µg/L高特异度预测不良神经预后。
  • 作者认为,NSE低于17 µg/L提示无严重缺氧缺血性脑病。
  • 作者认为,需考虑溶血和其他混杂因素对NSE解读的影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: To evaluate neuron-specific enolase (NSE) thresholds for prediction of neurological outcome after cardiac arrest and to analyze the influence of hemolysis and confounders.

METHODS: Retrospective analysis from a cardiac arrest registry. Determination of NSE serum concentration and hemolysis-index (h-index) 48-96 hours after cardiac arrest. Evaluation of neurological outcome using the Cerebral Performance Category score (CPC) at hospital discharge. Separate analyses considering CPC 1-3 and CPC 1-2 as good neurological outcome. Analysis of specificity and sensitivity for poor and good neurological outcome prediction with and without exclusion of hemolytic samples (h-index larger than 50).

RESULTS: Among 356 survivors three days after cardiac arrest, hemolysis was detected in 28 samples (7.9%). At a threshold of 60 µg/L, NSE predicted poor neurological outcome (CPC 4-5) in all samples with a specificity of 92% (86-95%) and sensitivity of 73% (66-79%). In non-hemolytic samples, specificity was 94% (89-97%) and sensitivity 70% (62-76%). At a threshold of 100 µg/L, specificity was 98% (95-100%, all samples) and 99% (95-100%, non-hemolytic samples), and sensitivity 58% (51-65%) and 55% (47-63%), respectively. Possible confounders for elevated NSE in patients with good neurological outcome were ECMO, malignancies, blood transfusions and acute brain diseases. Nine patients with NSE below 17 µg/L had CPC 5, all had plausible death causes other than hypoxic-ischemic encephalopathy.

CONCLUSIONS: NSE concentrations higher than 100 µg/L predicted poor neurological outcome with high specificity. An NSE less than 17 µg/L indicated absence of severe hypoxic-ischemic encephalopathy. Hemolysis and other confounders need to be considered.

INSTITUTIONAL PROTOCOL NUMBER: The local ethics committee (board name: Ethikkommission der Charité) approved this study by the number: EA2/066/23, approval date: 28th June 2023, study title "'ROSC' - Resuscitation Outcome Study."

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Czimmeck C, Kenda M, Aalberts N, et al. Confounders for prognostic accuracy of neuron-specific enolase after cardiac arrest: A retrospective cohort study. Resuscitation. 2023. PMID: 37683997. doi:10.1016/j.resuscitation.2023.109964

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。